Jeffrey J. Kovacs

Biochemistry, Genetics and Molecular Biology · Life Sciences

24h-index6.0kcitations85works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer, Hypoxia, and Metabolism(16), Amino Acid Enzymes and Metabolism(12), Biochemical and Molecular Research(12), Cancer Mechanisms and Therapy(9), Receptor Mechanisms and Signaling(8)

Publications85 total

Supplementary Figure S9 from Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma
2025Open Access
Supplementary Figure S3 from Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma
2025Open Access
Supplementary Figure S6 from Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma
2025Open Access
Supplementary Figure S5 from Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma
2025Open Access
Supplementary Materials and Methods S1 from Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma
2025Open Access
Supplementary Table S2 from Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma
2025Open Access
Supplementary Figure S7 from Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma
2025Open Access
Supplementary Figure S8 from Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma
2025Open Access
Supplementary Table S5 from Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma
2025Open Access
Supplementary Figure S1 from Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma
2025Open Access
Supplementary Figure S4 from Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma
2025Open Access
Supplementary Figure S2 from Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma
2025Open Access
Supplementary Table S4 from Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma
2025Open Access
Supplementary Table S3 from Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma
2025Open Access
Supplementary Table S1 from Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma
2025Open Access
Supplementary Data from Dual Inhibition of MEK and AXL Targets Tumor Cell Heterogeneity and Prevents Resistant Outgrowth Mediated by the Epithelial-to-Mesenchymal Transition in NSCLC
2023Open Access
Supplement Figures from Dual Inhibition of MEK and AXL Targets Tumor Cell Heterogeneity and Prevents Resistant Outgrowth Mediated by the Epithelial-to-Mesenchymal Transition in NSCLC
2023Open Access
Supplementary Data from Dual Inhibition of MEK and AXL Targets Tumor Cell Heterogeneity and Prevents Resistant Outgrowth Mediated by the Epithelial-to-Mesenchymal Transition in NSCLC
2023Open Access
Data from Allosteric SHP2 Inhibitor, IACS-13909, Overcomes EGFR-Dependent and EGFR-Independent Resistance Mechanisms toward Osimertinib
2023Open Access
Data from Allosteric SHP2 Inhibitor, IACS-13909, Overcomes EGFR-Dependent and EGFR-Independent Resistance Mechanisms toward Osimertinib
2023Open Access
page 1 of 5Next →

Frequent Co-authors

Timothy P. Heffernan(25), Christopher A. Bristow(18), Giulio Draetta(14), Maria Emilia Di Francesco(13), Nakia D. Spencer(12), Joseph R. Marszalek(11), Ningping Feng(11), Barbara Czakó(10), Jason P. Burke(10), Virginia Giuliani(10), Yongying Jiang(10), Don L. Gibbons(9), Timothy McAfoos(9), Jing Wang(9), Robert J. Lefkowitz(8), Érika Suzuki(8), Philip Jones(8), Michael Soth(8), Michael Peoples(7), Alessandro Carugo(7)